AMERICAN JOURNAL OF GASTROENTEROLOGY-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=1231616, encodeId=49d8123161614, content=请问期刊收版面费吗？open access的需要交多少钱呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220217/8786d50a2431425cbaf7dbc437d277a8/068b2a75786546cd8b23afd9cdc1d37b.jpeg, createdBy=30b74770079, createdName=皮卡皮卡丘, createdTime=Sun Jul 10 11:24:16 CST 2022, time=2022-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1213204, encodeId=6cf01213204a6, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：2022.01.19投稿 2022.01.24拒稿 审稿速度挺快的，编辑意见也很中肯, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e2a5469697, createdName=summer月, createdTime=Thu Apr 21 16:55:28 CST 2022, time=2022-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066522, encodeId=bc641066522e0, content=偏重的研究方向：IBD 经验分享：有中过的战友能提供一个投稿格式吗？投了一篇letter，返回来说格式不对。在它期刊网站没有模板，只有一个网页版的投稿说明。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77385688348, createdName=ms8000001907774095, createdTime=Wed Nov 03 10:39:32 CST 2021, time=2021-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926572, encodeId=b9fc9265e26a, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：3天秒拒，无理由, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb982473146, createdName=124403eem74暂无昵称, createdTime=Tue Feb 23 12:45:59 CST 2021, time=2021-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=908527, encodeId=027b90852e82, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：拒稿很快，没有实质yiji, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=51c02222748, createdName=12107b02m29(暂无昵称), createdTime=Wed Dec 16 13:05:08 CST 2020, time=2020-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=591503, encodeId=de6b59150325, content=请问with editor几天送审了后来？xmcx783 2020-01-14 00:00:00 发表: 投稿后with editor第7天了，不知道有没有机会送外审。, beContent=xmcx783 2020-01-14 00:00:00 发表: 投稿后with editor第7天了，不知道有没有机会送外审。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ee92574980, createdName=1258faf6m29暂无昵称, createdTime=Fri May 22 00:00:00 CST 2020, time=2020-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=587798, encodeId=7dca58e798b9, content=给各种战友友情提醒一下： 这个期刊不收动物模型的文章，谨慎选择。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0c222020507, createdName=壮壮一人暮, createdTime=Tue Mar 31 09:12:00 CST 2020, time=2020-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=565021, encodeId=8a2b565021a4, content=IBD临床研究一篇，2018年5月8日投稿，7月18日一审结果建议大修，9月13日修回，10月23日二审结果建议1个月小修，10月24日修回，11月8日接收。12月30日Proof。等待在线中。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=253, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3aca20850, createdName=zhu19820122, createdTime=Mon Dec 31 23:18:00 CST 2018, time=2018-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=563647, encodeId=d29256364e61, content=请问一下，这个杂志接收基础文章吗？最近做了一个分子在肠炎中的作用，临床，细胞，动物都有。并纯化了该分子蛋白证明其有临床治疗价值, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=211, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJezw9rLVo7scpm4bIb34WhXb0deaXB8picW5eMAazAJHqyt2iaj4Zw6Uecu7jrAcuWiax5TTGr2reoA/132, createdBy=02e72292772, createdName=Godmin, createdTime=Mon Nov 26 00:00:00 CST 2018, time=2018-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=562218, encodeId=83da5622186e, content=投了个图片报道，审稿一个月了，今天变成了 Awaiting Final Decision。。。。就一个审稿人，战友们给评估下，希望多大？担忧中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=268, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/c00242ccb692f0fc07af23dc30809e82/4340b0461b88d04d2cb3cf232a69b8df.jpg, createdBy=ee272000038, createdName=赤脚草医, createdTime=Sun Oct 21 11:04:00 CST 2018, time=2018-10-21, status=1, ipAttribution=)]

2022-07-10 皮卡皮卡丘

请问期刊收版面费吗？open access的需要交多少钱呢

95 0

[GetPortalCommentsPageByObjectIdResponse(id=1231616, encodeId=49d8123161614, content=请问期刊收版面费吗？open access的需要交多少钱呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220217/8786d50a2431425cbaf7dbc437d277a8/068b2a75786546cd8b23afd9cdc1d37b.jpeg, createdBy=30b74770079, createdName=皮卡皮卡丘, createdTime=Sun Jul 10 11:24:16 CST 2022, time=2022-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1213204, encodeId=6cf01213204a6, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：2022.01.19投稿 2022.01.24拒稿 审稿速度挺快的，编辑意见也很中肯, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e2a5469697, createdName=summer月, createdTime=Thu Apr 21 16:55:28 CST 2022, time=2022-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066522, encodeId=bc641066522e0, content=偏重的研究方向：IBD 经验分享：有中过的战友能提供一个投稿格式吗？投了一篇letter，返回来说格式不对。在它期刊网站没有模板，只有一个网页版的投稿说明。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77385688348, createdName=ms8000001907774095, createdTime=Wed Nov 03 10:39:32 CST 2021, time=2021-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926572, encodeId=b9fc9265e26a, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：3天秒拒，无理由, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb982473146, createdName=124403eem74暂无昵称, createdTime=Tue Feb 23 12:45:59 CST 2021, time=2021-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=908527, encodeId=027b90852e82, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：拒稿很快，没有实质yiji, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=51c02222748, createdName=12107b02m29(暂无昵称), createdTime=Wed Dec 16 13:05:08 CST 2020, time=2020-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=591503, encodeId=de6b59150325, content=请问with editor几天送审了后来？xmcx783 2020-01-14 00:00:00 发表: 投稿后with editor第7天了，不知道有没有机会送外审。, beContent=xmcx783 2020-01-14 00:00:00 发表: 投稿后with editor第7天了，不知道有没有机会送外审。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ee92574980, createdName=1258faf6m29暂无昵称, createdTime=Fri May 22 00:00:00 CST 2020, time=2020-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=587798, encodeId=7dca58e798b9, content=给各种战友友情提醒一下： 这个期刊不收动物模型的文章，谨慎选择。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0c222020507, createdName=壮壮一人暮, createdTime=Tue Mar 31 09:12:00 CST 2020, time=2020-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=565021, encodeId=8a2b565021a4, content=IBD临床研究一篇，2018年5月8日投稿，7月18日一审结果建议大修，9月13日修回，10月23日二审结果建议1个月小修，10月24日修回，11月8日接收。12月30日Proof。等待在线中。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=253, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3aca20850, createdName=zhu19820122, createdTime=Mon Dec 31 23:18:00 CST 2018, time=2018-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=563647, encodeId=d29256364e61, content=请问一下，这个杂志接收基础文章吗？最近做了一个分子在肠炎中的作用，临床，细胞，动物都有。并纯化了该分子蛋白证明其有临床治疗价值, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=211, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJezw9rLVo7scpm4bIb34WhXb0deaXB8picW5eMAazAJHqyt2iaj4Zw6Uecu7jrAcuWiax5TTGr2reoA/132, createdBy=02e72292772, createdName=Godmin, createdTime=Mon Nov 26 00:00:00 CST 2018, time=2018-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=562218, encodeId=83da5622186e, content=投了个图片报道，审稿一个月了，今天变成了 Awaiting Final Decision。。。。就一个审稿人，战友们给评估下，希望多大？担忧中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=268, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/c00242ccb692f0fc07af23dc30809e82/4340b0461b88d04d2cb3cf232a69b8df.jpg, createdBy=ee272000038, createdName=赤脚草医, createdTime=Sun Oct 21 11:04:00 CST 2018, time=2018-10-21, status=1, ipAttribution=)]

2022-04-21 summer月

审稿速度:1.0 | 投稿命中率:25.0
经验分享：2022.01.19投稿
2022.01.24拒稿
审稿速度挺快的，编辑意见也很中肯

73 0

[GetPortalCommentsPageByObjectIdResponse(id=1231616, encodeId=49d8123161614, content=请问期刊收版面费吗？open access的需要交多少钱呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220217/8786d50a2431425cbaf7dbc437d277a8/068b2a75786546cd8b23afd9cdc1d37b.jpeg, createdBy=30b74770079, createdName=皮卡皮卡丘, createdTime=Sun Jul 10 11:24:16 CST 2022, time=2022-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1213204, encodeId=6cf01213204a6, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：2022.01.19投稿 2022.01.24拒稿 审稿速度挺快的，编辑意见也很中肯, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e2a5469697, createdName=summer月, createdTime=Thu Apr 21 16:55:28 CST 2022, time=2022-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066522, encodeId=bc641066522e0, content=偏重的研究方向：IBD 经验分享：有中过的战友能提供一个投稿格式吗？投了一篇letter，返回来说格式不对。在它期刊网站没有模板，只有一个网页版的投稿说明。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77385688348, createdName=ms8000001907774095, createdTime=Wed Nov 03 10:39:32 CST 2021, time=2021-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926572, encodeId=b9fc9265e26a, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：3天秒拒，无理由, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb982473146, createdName=124403eem74暂无昵称, createdTime=Tue Feb 23 12:45:59 CST 2021, time=2021-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=908527, encodeId=027b90852e82, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：拒稿很快，没有实质yiji, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=51c02222748, createdName=12107b02m29(暂无昵称), createdTime=Wed Dec 16 13:05:08 CST 2020, time=2020-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=591503, encodeId=de6b59150325, content=请问with editor几天送审了后来？xmcx783 2020-01-14 00:00:00 发表: 投稿后with editor第7天了，不知道有没有机会送外审。, beContent=xmcx783 2020-01-14 00:00:00 发表: 投稿后with editor第7天了，不知道有没有机会送外审。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ee92574980, createdName=1258faf6m29暂无昵称, createdTime=Fri May 22 00:00:00 CST 2020, time=2020-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=587798, encodeId=7dca58e798b9, content=给各种战友友情提醒一下： 这个期刊不收动物模型的文章，谨慎选择。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0c222020507, createdName=壮壮一人暮, createdTime=Tue Mar 31 09:12:00 CST 2020, time=2020-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=565021, encodeId=8a2b565021a4, content=IBD临床研究一篇，2018年5月8日投稿，7月18日一审结果建议大修，9月13日修回，10月23日二审结果建议1个月小修，10月24日修回，11月8日接收。12月30日Proof。等待在线中。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=253, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3aca20850, createdName=zhu19820122, createdTime=Mon Dec 31 23:18:00 CST 2018, time=2018-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=563647, encodeId=d29256364e61, content=请问一下，这个杂志接收基础文章吗？最近做了一个分子在肠炎中的作用，临床，细胞，动物都有。并纯化了该分子蛋白证明其有临床治疗价值, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=211, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJezw9rLVo7scpm4bIb34WhXb0deaXB8picW5eMAazAJHqyt2iaj4Zw6Uecu7jrAcuWiax5TTGr2reoA/132, createdBy=02e72292772, createdName=Godmin, createdTime=Mon Nov 26 00:00:00 CST 2018, time=2018-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=562218, encodeId=83da5622186e, content=投了个图片报道，审稿一个月了，今天变成了 Awaiting Final Decision。。。。就一个审稿人，战友们给评估下，希望多大？担忧中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=268, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/c00242ccb692f0fc07af23dc30809e82/4340b0461b88d04d2cb3cf232a69b8df.jpg, createdBy=ee272000038, createdName=赤脚草医, createdTime=Sun Oct 21 11:04:00 CST 2018, time=2018-10-21, status=1, ipAttribution=)]

2021-11-03 ms8000001907774095

偏重的研究方向：IBD
经验分享：有中过的战友能提供一个投稿格式吗？投了一篇letter，返回来说格式不对。在它期刊网站没有模板，只有一个网页版的投稿说明。

80 0

[GetPortalCommentsPageByObjectIdResponse(id=1231616, encodeId=49d8123161614, content=请问期刊收版面费吗？open access的需要交多少钱呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220217/8786d50a2431425cbaf7dbc437d277a8/068b2a75786546cd8b23afd9cdc1d37b.jpeg, createdBy=30b74770079, createdName=皮卡皮卡丘, createdTime=Sun Jul 10 11:24:16 CST 2022, time=2022-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1213204, encodeId=6cf01213204a6, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：2022.01.19投稿 2022.01.24拒稿 审稿速度挺快的，编辑意见也很中肯, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e2a5469697, createdName=summer月, createdTime=Thu Apr 21 16:55:28 CST 2022, time=2022-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066522, encodeId=bc641066522e0, content=偏重的研究方向：IBD 经验分享：有中过的战友能提供一个投稿格式吗？投了一篇letter，返回来说格式不对。在它期刊网站没有模板，只有一个网页版的投稿说明。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77385688348, createdName=ms8000001907774095, createdTime=Wed Nov 03 10:39:32 CST 2021, time=2021-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926572, encodeId=b9fc9265e26a, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：3天秒拒，无理由, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb982473146, createdName=124403eem74暂无昵称, createdTime=Tue Feb 23 12:45:59 CST 2021, time=2021-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=908527, encodeId=027b90852e82, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：拒稿很快，没有实质yiji, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=51c02222748, createdName=12107b02m29(暂无昵称), createdTime=Wed Dec 16 13:05:08 CST 2020, time=2020-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=591503, encodeId=de6b59150325, content=请问with editor几天送审了后来？xmcx783 2020-01-14 00:00:00 发表: 投稿后with editor第7天了，不知道有没有机会送外审。, beContent=xmcx783 2020-01-14 00:00:00 发表: 投稿后with editor第7天了，不知道有没有机会送外审。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ee92574980, createdName=1258faf6m29暂无昵称, createdTime=Fri May 22 00:00:00 CST 2020, time=2020-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=587798, encodeId=7dca58e798b9, content=给各种战友友情提醒一下： 这个期刊不收动物模型的文章，谨慎选择。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0c222020507, createdName=壮壮一人暮, createdTime=Tue Mar 31 09:12:00 CST 2020, time=2020-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=565021, encodeId=8a2b565021a4, content=IBD临床研究一篇，2018年5月8日投稿，7月18日一审结果建议大修，9月13日修回，10月23日二审结果建议1个月小修，10月24日修回，11月8日接收。12月30日Proof。等待在线中。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=253, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3aca20850, createdName=zhu19820122, createdTime=Mon Dec 31 23:18:00 CST 2018, time=2018-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=563647, encodeId=d29256364e61, content=请问一下，这个杂志接收基础文章吗？最近做了一个分子在肠炎中的作用，临床，细胞，动物都有。并纯化了该分子蛋白证明其有临床治疗价值, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=211, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJezw9rLVo7scpm4bIb34WhXb0deaXB8picW5eMAazAJHqyt2iaj4Zw6Uecu7jrAcuWiax5TTGr2reoA/132, createdBy=02e72292772, createdName=Godmin, createdTime=Mon Nov 26 00:00:00 CST 2018, time=2018-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=562218, encodeId=83da5622186e, content=投了个图片报道，审稿一个月了，今天变成了 Awaiting Final Decision。。。。就一个审稿人，战友们给评估下，希望多大？担忧中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=268, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/c00242ccb692f0fc07af23dc30809e82/4340b0461b88d04d2cb3cf232a69b8df.jpg, createdBy=ee272000038, createdName=赤脚草医, createdTime=Sun Oct 21 11:04:00 CST 2018, time=2018-10-21, status=1, ipAttribution=)]

2021-02-23 124403eem74暂无昵称

审稿速度:1.0 | 投稿命中率:25.0
经验分享：3天秒拒，无理由

124 0

[GetPortalCommentsPageByObjectIdResponse(id=1231616, encodeId=49d8123161614, content=请问期刊收版面费吗？open access的需要交多少钱呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220217/8786d50a2431425cbaf7dbc437d277a8/068b2a75786546cd8b23afd9cdc1d37b.jpeg, createdBy=30b74770079, createdName=皮卡皮卡丘, createdTime=Sun Jul 10 11:24:16 CST 2022, time=2022-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1213204, encodeId=6cf01213204a6, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：2022.01.19投稿 2022.01.24拒稿 审稿速度挺快的，编辑意见也很中肯, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e2a5469697, createdName=summer月, createdTime=Thu Apr 21 16:55:28 CST 2022, time=2022-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066522, encodeId=bc641066522e0, content=偏重的研究方向：IBD 经验分享：有中过的战友能提供一个投稿格式吗？投了一篇letter，返回来说格式不对。在它期刊网站没有模板，只有一个网页版的投稿说明。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77385688348, createdName=ms8000001907774095, createdTime=Wed Nov 03 10:39:32 CST 2021, time=2021-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926572, encodeId=b9fc9265e26a, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：3天秒拒，无理由, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb982473146, createdName=124403eem74暂无昵称, createdTime=Tue Feb 23 12:45:59 CST 2021, time=2021-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=908527, encodeId=027b90852e82, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：拒稿很快，没有实质yiji, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=51c02222748, createdName=12107b02m29(暂无昵称), createdTime=Wed Dec 16 13:05:08 CST 2020, time=2020-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=591503, encodeId=de6b59150325, content=请问with editor几天送审了后来？xmcx783 2020-01-14 00:00:00 发表: 投稿后with editor第7天了，不知道有没有机会送外审。, beContent=xmcx783 2020-01-14 00:00:00 发表: 投稿后with editor第7天了，不知道有没有机会送外审。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ee92574980, createdName=1258faf6m29暂无昵称, createdTime=Fri May 22 00:00:00 CST 2020, time=2020-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=587798, encodeId=7dca58e798b9, content=给各种战友友情提醒一下： 这个期刊不收动物模型的文章，谨慎选择。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0c222020507, createdName=壮壮一人暮, createdTime=Tue Mar 31 09:12:00 CST 2020, time=2020-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=565021, encodeId=8a2b565021a4, content=IBD临床研究一篇，2018年5月8日投稿，7月18日一审结果建议大修，9月13日修回，10月23日二审结果建议1个月小修，10月24日修回，11月8日接收。12月30日Proof。等待在线中。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=253, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3aca20850, createdName=zhu19820122, createdTime=Mon Dec 31 23:18:00 CST 2018, time=2018-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=563647, encodeId=d29256364e61, content=请问一下，这个杂志接收基础文章吗？最近做了一个分子在肠炎中的作用，临床，细胞，动物都有。并纯化了该分子蛋白证明其有临床治疗价值, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=211, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJezw9rLVo7scpm4bIb34WhXb0deaXB8picW5eMAazAJHqyt2iaj4Zw6Uecu7jrAcuWiax5TTGr2reoA/132, createdBy=02e72292772, createdName=Godmin, createdTime=Mon Nov 26 00:00:00 CST 2018, time=2018-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=562218, encodeId=83da5622186e, content=投了个图片报道，审稿一个月了，今天变成了 Awaiting Final Decision。。。。就一个审稿人，战友们给评估下，希望多大？担忧中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=268, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/c00242ccb692f0fc07af23dc30809e82/4340b0461b88d04d2cb3cf232a69b8df.jpg, createdBy=ee272000038, createdName=赤脚草医, createdTime=Sun Oct 21 11:04:00 CST 2018, time=2018-10-21, status=1, ipAttribution=)]

2020-12-16 12107b02m29(暂无昵称)

审稿速度:1.0 | 投稿命中率:5.0
经验分享：拒稿很快，没有实质yiji

108 0

[GetPortalCommentsPageByObjectIdResponse(id=1231616, encodeId=49d8123161614, content=请问期刊收版面费吗？open access的需要交多少钱呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220217/8786d50a2431425cbaf7dbc437d277a8/068b2a75786546cd8b23afd9cdc1d37b.jpeg, createdBy=30b74770079, createdName=皮卡皮卡丘, createdTime=Sun Jul 10 11:24:16 CST 2022, time=2022-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1213204, encodeId=6cf01213204a6, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：2022.01.19投稿 2022.01.24拒稿 审稿速度挺快的，编辑意见也很中肯, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e2a5469697, createdName=summer月, createdTime=Thu Apr 21 16:55:28 CST 2022, time=2022-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066522, encodeId=bc641066522e0, content=偏重的研究方向：IBD 经验分享：有中过的战友能提供一个投稿格式吗？投了一篇letter，返回来说格式不对。在它期刊网站没有模板，只有一个网页版的投稿说明。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77385688348, createdName=ms8000001907774095, createdTime=Wed Nov 03 10:39:32 CST 2021, time=2021-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926572, encodeId=b9fc9265e26a, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：3天秒拒，无理由, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb982473146, createdName=124403eem74暂无昵称, createdTime=Tue Feb 23 12:45:59 CST 2021, time=2021-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=908527, encodeId=027b90852e82, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：拒稿很快，没有实质yiji, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=51c02222748, createdName=12107b02m29(暂无昵称), createdTime=Wed Dec 16 13:05:08 CST 2020, time=2020-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=591503, encodeId=de6b59150325, content=请问with editor几天送审了后来？xmcx783 2020-01-14 00:00:00 发表: 投稿后with editor第7天了，不知道有没有机会送外审。, beContent=xmcx783 2020-01-14 00:00:00 发表: 投稿后with editor第7天了，不知道有没有机会送外审。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ee92574980, createdName=1258faf6m29暂无昵称, createdTime=Fri May 22 00:00:00 CST 2020, time=2020-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=587798, encodeId=7dca58e798b9, content=给各种战友友情提醒一下： 这个期刊不收动物模型的文章，谨慎选择。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0c222020507, createdName=壮壮一人暮, createdTime=Tue Mar 31 09:12:00 CST 2020, time=2020-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=565021, encodeId=8a2b565021a4, content=IBD临床研究一篇，2018年5月8日投稿，7月18日一审结果建议大修，9月13日修回，10月23日二审结果建议1个月小修，10月24日修回，11月8日接收。12月30日Proof。等待在线中。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=253, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3aca20850, createdName=zhu19820122, createdTime=Mon Dec 31 23:18:00 CST 2018, time=2018-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=563647, encodeId=d29256364e61, content=请问一下，这个杂志接收基础文章吗？最近做了一个分子在肠炎中的作用，临床，细胞，动物都有。并纯化了该分子蛋白证明其有临床治疗价值, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=211, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJezw9rLVo7scpm4bIb34WhXb0deaXB8picW5eMAazAJHqyt2iaj4Zw6Uecu7jrAcuWiax5TTGr2reoA/132, createdBy=02e72292772, createdName=Godmin, createdTime=Mon Nov 26 00:00:00 CST 2018, time=2018-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=562218, encodeId=83da5622186e, content=投了个图片报道，审稿一个月了，今天变成了 Awaiting Final Decision。。。。就一个审稿人，战友们给评估下，希望多大？担忧中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=268, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/c00242ccb692f0fc07af23dc30809e82/4340b0461b88d04d2cb3cf232a69b8df.jpg, createdBy=ee272000038, createdName=赤脚草医, createdTime=Sun Oct 21 11:04:00 CST 2018, time=2018-10-21, status=1, ipAttribution=)]

2020-05-22 1258faf6m29暂无昵称

请问with editor几天送审了后来？xmcx783 2020-01-14 00:00:00 发表:
投稿后with editor第7天了，不知道有没有机会送外审。

xmcx783 2020-01-14 00:00:00 发表: 投稿后with editor第7天了，不知道有没有机会送外审。

141 0

[GetPortalCommentsPageByObjectIdResponse(id=1231616, encodeId=49d8123161614, content=请问期刊收版面费吗？open access的需要交多少钱呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220217/8786d50a2431425cbaf7dbc437d277a8/068b2a75786546cd8b23afd9cdc1d37b.jpeg, createdBy=30b74770079, createdName=皮卡皮卡丘, createdTime=Sun Jul 10 11:24:16 CST 2022, time=2022-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1213204, encodeId=6cf01213204a6, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：2022.01.19投稿 2022.01.24拒稿 审稿速度挺快的，编辑意见也很中肯, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e2a5469697, createdName=summer月, createdTime=Thu Apr 21 16:55:28 CST 2022, time=2022-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066522, encodeId=bc641066522e0, content=偏重的研究方向：IBD 经验分享：有中过的战友能提供一个投稿格式吗？投了一篇letter，返回来说格式不对。在它期刊网站没有模板，只有一个网页版的投稿说明。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77385688348, createdName=ms8000001907774095, createdTime=Wed Nov 03 10:39:32 CST 2021, time=2021-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926572, encodeId=b9fc9265e26a, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：3天秒拒，无理由, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb982473146, createdName=124403eem74暂无昵称, createdTime=Tue Feb 23 12:45:59 CST 2021, time=2021-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=908527, encodeId=027b90852e82, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：拒稿很快，没有实质yiji, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=51c02222748, createdName=12107b02m29(暂无昵称), createdTime=Wed Dec 16 13:05:08 CST 2020, time=2020-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=591503, encodeId=de6b59150325, content=请问with editor几天送审了后来？xmcx783 2020-01-14 00:00:00 发表: 投稿后with editor第7天了，不知道有没有机会送外审。, beContent=xmcx783 2020-01-14 00:00:00 发表: 投稿后with editor第7天了，不知道有没有机会送外审。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ee92574980, createdName=1258faf6m29暂无昵称, createdTime=Fri May 22 00:00:00 CST 2020, time=2020-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=587798, encodeId=7dca58e798b9, content=给各种战友友情提醒一下： 这个期刊不收动物模型的文章，谨慎选择。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0c222020507, createdName=壮壮一人暮, createdTime=Tue Mar 31 09:12:00 CST 2020, time=2020-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=565021, encodeId=8a2b565021a4, content=IBD临床研究一篇，2018年5月8日投稿，7月18日一审结果建议大修，9月13日修回，10月23日二审结果建议1个月小修，10月24日修回，11月8日接收。12月30日Proof。等待在线中。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=253, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3aca20850, createdName=zhu19820122, createdTime=Mon Dec 31 23:18:00 CST 2018, time=2018-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=563647, encodeId=d29256364e61, content=请问一下，这个杂志接收基础文章吗？最近做了一个分子在肠炎中的作用，临床，细胞，动物都有。并纯化了该分子蛋白证明其有临床治疗价值, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=211, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJezw9rLVo7scpm4bIb34WhXb0deaXB8picW5eMAazAJHqyt2iaj4Zw6Uecu7jrAcuWiax5TTGr2reoA/132, createdBy=02e72292772, createdName=Godmin, createdTime=Mon Nov 26 00:00:00 CST 2018, time=2018-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=562218, encodeId=83da5622186e, content=投了个图片报道，审稿一个月了，今天变成了 Awaiting Final Decision。。。。就一个审稿人，战友们给评估下，希望多大？担忧中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=268, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/c00242ccb692f0fc07af23dc30809e82/4340b0461b88d04d2cb3cf232a69b8df.jpg, createdBy=ee272000038, createdName=赤脚草医, createdTime=Sun Oct 21 11:04:00 CST 2018, time=2018-10-21, status=1, ipAttribution=)]

2020-03-31 壮壮一人暮

给各种战友友情提醒一下：
这个期刊不收动物模型的文章，谨慎选择。

165 0

[GetPortalCommentsPageByObjectIdResponse(id=1231616, encodeId=49d8123161614, content=请问期刊收版面费吗？open access的需要交多少钱呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220217/8786d50a2431425cbaf7dbc437d277a8/068b2a75786546cd8b23afd9cdc1d37b.jpeg, createdBy=30b74770079, createdName=皮卡皮卡丘, createdTime=Sun Jul 10 11:24:16 CST 2022, time=2022-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1213204, encodeId=6cf01213204a6, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：2022.01.19投稿 2022.01.24拒稿 审稿速度挺快的，编辑意见也很中肯, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e2a5469697, createdName=summer月, createdTime=Thu Apr 21 16:55:28 CST 2022, time=2022-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066522, encodeId=bc641066522e0, content=偏重的研究方向：IBD 经验分享：有中过的战友能提供一个投稿格式吗？投了一篇letter，返回来说格式不对。在它期刊网站没有模板，只有一个网页版的投稿说明。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77385688348, createdName=ms8000001907774095, createdTime=Wed Nov 03 10:39:32 CST 2021, time=2021-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926572, encodeId=b9fc9265e26a, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：3天秒拒，无理由, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb982473146, createdName=124403eem74暂无昵称, createdTime=Tue Feb 23 12:45:59 CST 2021, time=2021-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=908527, encodeId=027b90852e82, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：拒稿很快，没有实质yiji, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=51c02222748, createdName=12107b02m29(暂无昵称), createdTime=Wed Dec 16 13:05:08 CST 2020, time=2020-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=591503, encodeId=de6b59150325, content=请问with editor几天送审了后来？xmcx783 2020-01-14 00:00:00 发表: 投稿后with editor第7天了，不知道有没有机会送外审。, beContent=xmcx783 2020-01-14 00:00:00 发表: 投稿后with editor第7天了，不知道有没有机会送外审。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ee92574980, createdName=1258faf6m29暂无昵称, createdTime=Fri May 22 00:00:00 CST 2020, time=2020-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=587798, encodeId=7dca58e798b9, content=给各种战友友情提醒一下： 这个期刊不收动物模型的文章，谨慎选择。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0c222020507, createdName=壮壮一人暮, createdTime=Tue Mar 31 09:12:00 CST 2020, time=2020-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=565021, encodeId=8a2b565021a4, content=IBD临床研究一篇，2018年5月8日投稿，7月18日一审结果建议大修，9月13日修回，10月23日二审结果建议1个月小修，10月24日修回，11月8日接收。12月30日Proof。等待在线中。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=253, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3aca20850, createdName=zhu19820122, createdTime=Mon Dec 31 23:18:00 CST 2018, time=2018-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=563647, encodeId=d29256364e61, content=请问一下，这个杂志接收基础文章吗？最近做了一个分子在肠炎中的作用，临床，细胞，动物都有。并纯化了该分子蛋白证明其有临床治疗价值, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=211, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJezw9rLVo7scpm4bIb34WhXb0deaXB8picW5eMAazAJHqyt2iaj4Zw6Uecu7jrAcuWiax5TTGr2reoA/132, createdBy=02e72292772, createdName=Godmin, createdTime=Mon Nov 26 00:00:00 CST 2018, time=2018-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=562218, encodeId=83da5622186e, content=投了个图片报道，审稿一个月了，今天变成了 Awaiting Final Decision。。。。就一个审稿人，战友们给评估下，希望多大？担忧中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=268, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/c00242ccb692f0fc07af23dc30809e82/4340b0461b88d04d2cb3cf232a69b8df.jpg, createdBy=ee272000038, createdName=赤脚草医, createdTime=Sun Oct 21 11:04:00 CST 2018, time=2018-10-21, status=1, ipAttribution=)]

2018-12-31 zhu19820122

IBD临床研究一篇，2018年5月8日投稿，7月18日一审结果建议大修，9月13日修回，10月23日二审结果建议1个月小修，10月24日修回，11月8日接收。12月30日Proof。等待在线中。

253 0

[GetPortalCommentsPageByObjectIdResponse(id=1231616, encodeId=49d8123161614, content=请问期刊收版面费吗？open access的需要交多少钱呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220217/8786d50a2431425cbaf7dbc437d277a8/068b2a75786546cd8b23afd9cdc1d37b.jpeg, createdBy=30b74770079, createdName=皮卡皮卡丘, createdTime=Sun Jul 10 11:24:16 CST 2022, time=2022-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1213204, encodeId=6cf01213204a6, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：2022.01.19投稿 2022.01.24拒稿 审稿速度挺快的，编辑意见也很中肯, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e2a5469697, createdName=summer月, createdTime=Thu Apr 21 16:55:28 CST 2022, time=2022-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066522, encodeId=bc641066522e0, content=偏重的研究方向：IBD 经验分享：有中过的战友能提供一个投稿格式吗？投了一篇letter，返回来说格式不对。在它期刊网站没有模板，只有一个网页版的投稿说明。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77385688348, createdName=ms8000001907774095, createdTime=Wed Nov 03 10:39:32 CST 2021, time=2021-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926572, encodeId=b9fc9265e26a, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：3天秒拒，无理由, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb982473146, createdName=124403eem74暂无昵称, createdTime=Tue Feb 23 12:45:59 CST 2021, time=2021-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=908527, encodeId=027b90852e82, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：拒稿很快，没有实质yiji, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=51c02222748, createdName=12107b02m29(暂无昵称), createdTime=Wed Dec 16 13:05:08 CST 2020, time=2020-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=591503, encodeId=de6b59150325, content=请问with editor几天送审了后来？xmcx783 2020-01-14 00:00:00 发表: 投稿后with editor第7天了，不知道有没有机会送外审。, beContent=xmcx783 2020-01-14 00:00:00 发表: 投稿后with editor第7天了，不知道有没有机会送外审。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ee92574980, createdName=1258faf6m29暂无昵称, createdTime=Fri May 22 00:00:00 CST 2020, time=2020-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=587798, encodeId=7dca58e798b9, content=给各种战友友情提醒一下： 这个期刊不收动物模型的文章，谨慎选择。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0c222020507, createdName=壮壮一人暮, createdTime=Tue Mar 31 09:12:00 CST 2020, time=2020-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=565021, encodeId=8a2b565021a4, content=IBD临床研究一篇，2018年5月8日投稿，7月18日一审结果建议大修，9月13日修回，10月23日二审结果建议1个月小修，10月24日修回，11月8日接收。12月30日Proof。等待在线中。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=253, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3aca20850, createdName=zhu19820122, createdTime=Mon Dec 31 23:18:00 CST 2018, time=2018-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=563647, encodeId=d29256364e61, content=请问一下，这个杂志接收基础文章吗？最近做了一个分子在肠炎中的作用，临床，细胞，动物都有。并纯化了该分子蛋白证明其有临床治疗价值, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=211, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJezw9rLVo7scpm4bIb34WhXb0deaXB8picW5eMAazAJHqyt2iaj4Zw6Uecu7jrAcuWiax5TTGr2reoA/132, createdBy=02e72292772, createdName=Godmin, createdTime=Mon Nov 26 00:00:00 CST 2018, time=2018-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=562218, encodeId=83da5622186e, content=投了个图片报道，审稿一个月了，今天变成了 Awaiting Final Decision。。。。就一个审稿人，战友们给评估下，希望多大？担忧中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=268, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/c00242ccb692f0fc07af23dc30809e82/4340b0461b88d04d2cb3cf232a69b8df.jpg, createdBy=ee272000038, createdName=赤脚草医, createdTime=Sun Oct 21 11:04:00 CST 2018, time=2018-10-21, status=1, ipAttribution=)]

2018-11-26 Godmin

请问一下，这个杂志接收基础文章吗？最近做了一个分子在肠炎中的作用，临床，细胞，动物都有。并纯化了该分子蛋白证明其有临床治疗价值

211 0

[GetPortalCommentsPageByObjectIdResponse(id=1231616, encodeId=49d8123161614, content=请问期刊收版面费吗？open access的需要交多少钱呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220217/8786d50a2431425cbaf7dbc437d277a8/068b2a75786546cd8b23afd9cdc1d37b.jpeg, createdBy=30b74770079, createdName=皮卡皮卡丘, createdTime=Sun Jul 10 11:24:16 CST 2022, time=2022-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1213204, encodeId=6cf01213204a6, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：2022.01.19投稿 2022.01.24拒稿 审稿速度挺快的，编辑意见也很中肯, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e2a5469697, createdName=summer月, createdTime=Thu Apr 21 16:55:28 CST 2022, time=2022-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066522, encodeId=bc641066522e0, content=偏重的研究方向：IBD 经验分享：有中过的战友能提供一个投稿格式吗？投了一篇letter，返回来说格式不对。在它期刊网站没有模板，只有一个网页版的投稿说明。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77385688348, createdName=ms8000001907774095, createdTime=Wed Nov 03 10:39:32 CST 2021, time=2021-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926572, encodeId=b9fc9265e26a, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：3天秒拒，无理由, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb982473146, createdName=124403eem74暂无昵称, createdTime=Tue Feb 23 12:45:59 CST 2021, time=2021-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=908527, encodeId=027b90852e82, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：拒稿很快，没有实质yiji, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=51c02222748, createdName=12107b02m29(暂无昵称), createdTime=Wed Dec 16 13:05:08 CST 2020, time=2020-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=591503, encodeId=de6b59150325, content=请问with editor几天送审了后来？xmcx783 2020-01-14 00:00:00 发表: 投稿后with editor第7天了，不知道有没有机会送外审。, beContent=xmcx783 2020-01-14 00:00:00 发表: 投稿后with editor第7天了，不知道有没有机会送外审。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ee92574980, createdName=1258faf6m29暂无昵称, createdTime=Fri May 22 00:00:00 CST 2020, time=2020-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=587798, encodeId=7dca58e798b9, content=给各种战友友情提醒一下： 这个期刊不收动物模型的文章，谨慎选择。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0c222020507, createdName=壮壮一人暮, createdTime=Tue Mar 31 09:12:00 CST 2020, time=2020-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=565021, encodeId=8a2b565021a4, content=IBD临床研究一篇，2018年5月8日投稿，7月18日一审结果建议大修，9月13日修回，10月23日二审结果建议1个月小修，10月24日修回，11月8日接收。12月30日Proof。等待在线中。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=253, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3aca20850, createdName=zhu19820122, createdTime=Mon Dec 31 23:18:00 CST 2018, time=2018-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=563647, encodeId=d29256364e61, content=请问一下，这个杂志接收基础文章吗？最近做了一个分子在肠炎中的作用，临床，细胞，动物都有。并纯化了该分子蛋白证明其有临床治疗价值, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=211, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJezw9rLVo7scpm4bIb34WhXb0deaXB8picW5eMAazAJHqyt2iaj4Zw6Uecu7jrAcuWiax5TTGr2reoA/132, createdBy=02e72292772, createdName=Godmin, createdTime=Mon Nov 26 00:00:00 CST 2018, time=2018-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=562218, encodeId=83da5622186e, content=投了个图片报道，审稿一个月了，今天变成了 Awaiting Final Decision。。。。就一个审稿人，战友们给评估下，希望多大？担忧中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=268, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/c00242ccb692f0fc07af23dc30809e82/4340b0461b88d04d2cb3cf232a69b8df.jpg, createdBy=ee272000038, createdName=赤脚草医, createdTime=Sun Oct 21 11:04:00 CST 2018, time=2018-10-21, status=1, ipAttribution=)]

2018-10-21 赤脚草医

投了个图片报道，审稿一个月了，今天变成了 Awaiting Final Decision。。。。就一个审稿人，战友们给评估下，希望多大？担忧中

268 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务